Walpar Nutritions Limited (NSE:WALPAR)
47.85
+1.95 (4.25%)
At close: Dec 23, 2025
Walpar Nutritions Revenue
Walpar Nutritions had revenue of 366.21M INR in the half year ending September 30, 2025, with 17.38% growth. This brings the company's revenue in the last twelve months to 757.46M, up 17.66% year-over-year. In the fiscal year ending March 31, 2025, Walpar Nutritions had annual revenue of 719.60M with 14.93% growth.
Revenue (ttm)
757.46M
Revenue Growth
+17.66%
P/S Ratio
0.59
Revenue / Employee
n/a
Employees
n/a
Market Cap
449.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 719.60M | 93.47M | 14.93% |
| Mar 31, 2024 | 626.13M | 272.57M | 77.10% |
| Mar 31, 2023 | 353.55M | 85.81M | 32.05% |
| Mar 31, 2022 | 267.74M | 85.69M | 47.07% |
| Mar 31, 2021 | 182.05M | 14.92M | 8.93% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Murae Organisor | 8.59B |
| Welcure Drugs and Pharmaceuticals | 3.66B |
| Deccan Health Care | 847.12M |
| JFL Life Sciences | 744.78M |
| Onyx Biotec | 663.87M |
| Gujarat Terce Laboratories | 501.95M |
| Panjon | 463.51M |
| Biofil Chemicals and Pharmaceuticals | 455.49M |